A Phase 2 interventional study of 4-month FDC-based regimen and 3-month BDCZ regimen in Tuberculosis, sponsored by Huashan Hospital. Recruiting at 13 sites in China. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Huashan Hospital · Phase 2, Interventional, and Treatment
The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis.
The main questions it aims to answer are:
Researchers will compare the 3-month BDCZ regimen and the 4-month FDC regimen with the standard 6-month treatment regimen to evaluate their efficacy and safety in children with non-severe, drug-susceptible pulmonary tuberculosis.
Participants will be randomly assigned to one of three treatment groups and will receive the allocated regimen. They will undergo clinical assessments and safety monitoring during treatment, with follow-up to assess treatment outcomes, tuberculosis recurrence, and tuberculosis-free survival at 12, 18, and 24 months after treatment initiation.
Tuberculosis remains an important cause of morbidity in children. Shortening treatment duration while maintaining efficacy and safety is a key priority in the management of childhood tuberculosis. Evidence from previous studies has demonstrated that a 4-month treatment regimen can be effective for children with non-severe, drug-susceptible pulmonary tuberculosis. However, the implementation of short-course treatment in China remains challenging, partly because of limited availability of child-friendly formulations that support accurate dosing and treatment adherence.
Newer anti-tuberculosis drugs and combinations with potent bactericidal activity offer opportunities to further shorten treatment duration. However, clinical evidence supporting the use of these regimens in children with drug-susceptible tuberculosis remains limited. In addition, child-friendly fixed-dose combination (FDC) formulations may facilitate the implementation of short-course treatment by simplifying drug administration and improving dosing accuracy and adherence.
This Phase II, multicenter, open-label, randomized controlled trial will evaluate the efficacy and safety of two short-course treatment regimens in children with non-severe, drug-susceptible pulmonary tuberculosis. The study includes three treatment groups: a 3-month regimen containing bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ); a 4-month FDC-based regimen; and the standard 6-month treatment regimen as the control.
The study will assess whether the short-course regimens provide favorable treatment outcomes while maintaining an acceptable safety profile. Efficacy assessments will include tuberculosis-free survival, treatment success, treatment failure, and tuberculosis recurrence. Safety assessments will focus on adverse events, including grade 3 or higher adverse events.
Participants will receive the treatment assigned through randomization and will undergo clinical assessments and safety monitoring during treatment. Follow-up after treatment initiation will evaluate longer-term treatment outcomes, including tuberculosis recurrence and tuberculosis-free survival.
The findings of this study will provide clinical evidence on the potential use of shorter treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis and may inform the development and implementation of more child-friendly treatment strategies.
1,436 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.
This study's planned enrollment of 90 is below the median of 150 across 963 interventional studies indexed under Tuberculosis.
Browse Tuberculosis studies →Huashan Hospital is the lead sponsor of 247 studies on the registry; 105 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: 4-month FDC-based regimen
Drug: 3-month BDCZ regimen
Drug: Standard 6-month treatment regimen
4-month fixed-dose combination (FDC) regimen
Also known as: 4FDC
3-month bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ) regimen
Also known as: 3BDCZ
Standard 6-month treatment regimen, namely 2HRZ(E)/HR.
Also known as: 2HRZ(E)/4HR
Tuberculosis-free survival at 12 months
Proportion of participants alive and free of tuberculosis at 12 months after treatment initiation.
Time frame: 12 months after treatment initiation
Incidence of grade 3 or higher adverse events
Proportion of participants experiencing one or more grade 3 or higher adverse events during treatment.
Time frame: From treatment initiation to the end of the assigned treatment regimen (3, 4, or 6 months)
Tuberculosis recurrence at 12 months
Proportion of participants who experience tuberculosis recurrence within 12 months after treatment initiation.
Time frame: 12 months after treatment initiation
Treatment success and treatment failure at the end of treatment
Proportions of participants classified as having treatment success or treatment failure according to the protocol-defined physician assessment at the end of the assigned treatment regimen.
Time frame: At the end of the assigned treatment regimen (3, 4, or 6 months)
Tuberculosis-free survival at 18 and 24 months
Proportion of participants alive and free of tuberculosis at 18 and 24 months after treatment initiation.
Time frame: 18 and 24 months after treatment initiation
Tuberculosis recurrence at 18 and 24 months
Proportion of participants who experience tuberculosis recurrence within 18 and 24 months after treatment initiation.
Time frame: 18 and 24 months after treatment initiation
Clinical outcomes at the end of follow-up
Proportions of participants with favorable and unfavorable clinical outcomes at the end of follow-up, as defined in the study protocol.
Time frame: 24 months after treatment initiation
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.